Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 9

The most critical question when reading a meta-analysis report: Is it comparing apples with apples or apples with oranges?

Pages
701–708
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

An example of meta-analyses with a study selection bias is a meta-analysis of over 160,000 patients in 20 clinical trials, published in Eur Heart J in 2012 by van Vark, which concluded that the significant effect of renin-angiotensin-aldosterone system (RAAS) inhibition on all-cause mortality was limited to the class of angiotensin-converting enzyme inhibitors (ACEIs), whereas no mortality reduction could be demonstrated with angiotensin receptor blockers (ARBs).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: While the number of meta-analyses published has increased recently, most of them have problems in the design, analysis, and/or presentation.
📊
Key Findings & Data:An example of meta-analyses with a study selection bias is a meta-analysis of over 160,000 patients in 20 clinical trials, published in Eur Heart J in 2012 by van Vark, which concluded that the significant effect of renin-angiotensin-aldosterone system (RAAS) inhibition on all-cause mortality was limited to the class of angiotensin-converting enzyme inhibitors (ACEIs), whereas no mortality reduction could be demonstrated with angiotensin receptor blockers (ARBs).
💡
Conclusion & Impact:The results were similar in the second and third steps.Conclusion: The studies to be included in meta-analyses, particularly comparing ACEIs and ARBs, should be chosen carefully
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: While the number of meta-analyses published has increased recently, most of them have problems in the design, analysis, and/or presentation. An example of meta-analyses with a study selection bias is a meta-analysis of over 160,000 patients in 20 clinical trials, published in Eur Heart J in 2012 by van Vark, which concluded that the significant effect of renin-angiotensin-aldosterone system (RAAS) inhibition on all-cause mortality was limited to the class of angiotensin-converting enzyme inhibitors (ACEIs), whereas no mortality reduction could be demonstrated with angiotensin receptor blockers (ARBs). Here, we aimed to discuss how to select studies for a meta-analysis and to present our results of a re-analysis of the van Vark data.Methods: The data were re-analyzed in three steps: firstly, only ACEI/ARB-based studies (4 ACEI and 12 ARB studies) were included; secondly, placebo-controlled studies were excluded, and 10 studies left were analyzed; and thirdly, 2 studies that were retracted after the manuscript of van Vark had been published were excluded. The final analysis included 8 studies with ~65,000 patients (3 ACEI and 5 ARB studies).Results: The hazard ratios for all-cause mortality and cardiovascular mortality were 0.992 (95% CI 0.899-1.095; p=0.875) and 1.017 (0.932-1.110; p=0.703) for the ACEI versus control group and 1.007 (0.958-1.059; p=0.778) and 0.967 (0.911-1.025; p=0.258) for the ARB versus control group in the first step. The results were similar in the second and third steps.Conclusion: The studies to be included in meta-analyses, particularly comparing ACEIs and ARBs, should be chosen carefully

🔖

Cite This Article

KIZILIRMAK, P., ÖZDEMİR, O., ÖNGEN, Z. (2015). The most critical question when reading a meta-analysis report: Is it comparing apples with apples or apples with oranges?. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 9, 701–708. https://ajindex.com/articles/367260

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med 2001
  2. [CrossRef] 2. Crowther M, Lim W, Crowther MA. Systematic review and metaanalysis methodology. Blood 2010
  3. [CrossRef] 3. Walker E, Hernandez AV, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med 2008
  4. [CrossRef] 4. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158.998 patients. Eur Heart J 2012
  5. [CrossRef] 5. Donzelli A. Reduction in all-cause mortality: from ACE inhibitors or from associated drugs? Eur Heart J Published online June 25, 2012. Available from: http://www.researchgate.net/publication/261401249 6. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007
  6. [CrossRef] 7. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005
  7. [CrossRef] 8. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008
  8. [CrossRef] 9. Ferrari R, Boersma E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther 2013
  9. [CrossRef] 10. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002
  10. [CrossRef] 11. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis (Statistics in Practice). West Sussex, UK